Unveiling INM-901
InMed completes the screening process in its neurodegenerative diseases program. InMed took a significant step forward in its INM-900 series program after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate. InMed launched the program in November 2022, targeting the use of proprietary cannabinoid analogs to treat neurodegenerative diseases after its research had identified two promising cannabinoid analog candidates warranting further investigation in in vivo studies. Next steps. InMed will now be advancing its final selected candidate for further preclinical study under nomenclature INM-901. Planning is underway for the next stage of advanced preclinical studies, which will include drug metabolism (elimination of the substance from the body), pharmacokinetics (how the body interacts with the administered drug), and the initiation of pharmaceutical drug development activities such as manufacturing and formulation. A novel approach to Alzheimer’s. Although still in the early stages of research and years away from gaining visibility on the program’s prospects of ultimate success, early in vitro studies of INM-901 have demonstrated its potential to target several biological pathways associated with Alzheimer's. These studies show that INM-901 treated groups not only display neuroprotection in the presence of toxic amyloid plaques (long thought to be a cause of Alzheimer’s), but also extended neurite length, a potential marker for improved neuronal function. Furthermore, INM-901 demonstrated favorable results in an in vivo preclinical Alzheimer’s proof-of-concept model, demonstrating improved behavioral, cognitive, and memory outcomes in treated groups. While currently available disease-modifying treatments focus on the removal of amyloid plaques, the potential to improve neuronal function would be transformative. InMed to raise $5.2 million. InMed also announced that it is raising aggregate gross proceeds of $5.2 million through a private placement of shares or pre-funded warrants in lieu and a preferred investment option exercise. The net proceeds will be used to continue development of InMed’s pharmaceutical drug pipeline, support BayMedica’s commercial business, and for general working capital purposes.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.